Abstract
Anti-tuberculosis drug induced (ATD) hepatotoxicity is uncommon and unpredictable. It might be related to drug itself or reactive metabolites derived from the drugs in vivo. Several demographic characteristics, such as race, age, sex, body mass index, alcohol intake, have been reported to be susceptibility risk factors for hepatotoxicity related to ATDs. There is now evidence that genetic variations or polymorphisms in biotransformation or detoxification systems controlled by NAT2, GSTM1 etc., might modulate the toxic effects of some drugs. Since prevalences of polymorphisms are different in different ethnic populations, the incidences of ATD hepatotoxicity vary in populations. Thus, knowledge of prevalences of polymorphisms in these genes in a population, prior to medication, may be useful in evaluating the risk and controlling ATD hepatotoxicity.
Keywords: anti-tuberculosis drugs, hepatotoxicity, polymorphism, gstm1, nat2, cyp genes
Current Pharmacogenomics
Title: Anti-Tuberculosis Drug Induced Hepatotoxicity and Genetic Polymorphisms in Drug-metabolizing Genes
Volume: 1 Issue: 2
Author(s): Bidyut Roy
Affiliation:
Keywords: anti-tuberculosis drugs, hepatotoxicity, polymorphism, gstm1, nat2, cyp genes
Abstract: Anti-tuberculosis drug induced (ATD) hepatotoxicity is uncommon and unpredictable. It might be related to drug itself or reactive metabolites derived from the drugs in vivo. Several demographic characteristics, such as race, age, sex, body mass index, alcohol intake, have been reported to be susceptibility risk factors for hepatotoxicity related to ATDs. There is now evidence that genetic variations or polymorphisms in biotransformation or detoxification systems controlled by NAT2, GSTM1 etc., might modulate the toxic effects of some drugs. Since prevalences of polymorphisms are different in different ethnic populations, the incidences of ATD hepatotoxicity vary in populations. Thus, knowledge of prevalences of polymorphisms in these genes in a population, prior to medication, may be useful in evaluating the risk and controlling ATD hepatotoxicity.
Export Options
About this article
Cite this article as:
Roy Bidyut, Anti-Tuberculosis Drug Induced Hepatotoxicity and Genetic Polymorphisms in Drug-metabolizing Genes, Current Pharmacogenomics 2003; 1 (2) . https://dx.doi.org/10.2174/1570160033476340
DOI https://dx.doi.org/10.2174/1570160033476340 |
Print ISSN 1570-1603 |
Publisher Name Bentham Science Publisher |
Online ISSN 1570-1603 |
Related Articles
-
Size Matters - Nanotechnology and Therapeutics in Rheumatology and Immunology
Current Rheumatology Reviews Bacterial Proteases in Disease – Role in Intracellular Survival, Evasion of Coagulation/ Fibrinolysis Innate Defenses, Toxicoses and Viral Infections
Current Pharmaceutical Design Recent Developments in the Transformation of 3-amino-2-azetidinones
Current Organic Chemistry Prediction of Translation Initiation Site in Bacterial and Archaeal Genomes
Current Bioinformatics CYP1A2, CYP2A6, CYP2B6, CYP3A4 and CYP3A5 Polymorphisms in Two Bantu-Speaking Populations from Cameroon and South Africa: Implications for Global Pharmacogenetics
Current Pharmacogenomics and Personalized Medicine Disruption of Circadian Rhythms in Critical Illness - A Role of Hyperoxia-Induced Lung Injury
Current Pharmaceutical Design Anti-Tuberculosis Activity of α-Helical Antimicrobial Peptides: De Novo Designed L- and D-Enantiomers Versus L- and D-LL37
Protein & Peptide Letters Unified Multi-target Approach for the Rational in silico Design of Anti-bladder Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Recent Advancements in Antimycobacterial and Antifungal Drugs: A Patent Perspective
Recent Patents on Biotechnology Synthesis, Molecular Docking, and <i>In vitro</i> Antimycobacterial Studies on N'-arylidene-4-nitrobenzohydrazides
Recent Advances in Anti-Infective Drug Discovery Virtual Screening Techniques and Current Computational Infrastructures
Current Pharmaceutical Design Phospholipase D Inhibition: Beneficial and Harmful Consequences for a Double-Dealer Enzyme
Current Enzyme Inhibition Discovery of Medically Significant Lantibiotics
Current Drug Discovery Technologies Adhesion Molecules and Kinases Involved in γ δ T Cells Migratory Pathways:Implications for Viral and Autoimmune Diseases
Current Medicinal Chemistry Teaching Pharmacogenetics in Low and Middle-Income Countries: Team Based Learning and Lessons Learned at the American University of Beirut
Current Pharmacogenomics and Personalized Medicine Recent Developments in Protein and Cell-Targeted Aptamer Selection and Applications
Current Medicinal Chemistry Burkholderia mallei and Burkholderia pseudomallei: The Causative Micro-organisms of Glanders and Melioidosis
Recent Patents on Anti-Infective Drug Discovery Solubilization and Antitumor Activity of Oleanolic Acid Lysinate
Current Analytical Chemistry Identification of Genes for a Complex Trait: Examples from Hypertension
Current Pharmaceutical Biotechnology Heparin Oligosaccharides as Potential Therapeutic Agents in Senile Dementia
Current Pharmaceutical Design